DE69522955T2 - Okulares hypotensium - Google Patents

Okulares hypotensium

Info

Publication number
DE69522955T2
DE69522955T2 DE69522955T DE69522955T DE69522955T2 DE 69522955 T2 DE69522955 T2 DE 69522955T2 DE 69522955 T DE69522955 T DE 69522955T DE 69522955 T DE69522955 T DE 69522955T DE 69522955 T2 DE69522955 T2 DE 69522955T2
Authority
DE
Germany
Prior art keywords
group
formula
compound
alkyl group
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69522955T
Other languages
German (de)
English (en)
Other versions
DE69522955D1 (de
Inventor
Tsunemichi Hosokawa
Hiroaki Yanagisawa
Tomihisa Yokoyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of DE69522955D1 publication Critical patent/DE69522955D1/de
Publication of DE69522955T2 publication Critical patent/DE69522955T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69522955T 1994-03-16 1995-03-16 Okulares hypotensium Expired - Fee Related DE69522955T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4540494 1994-03-16
PCT/JP1995/000444 WO1995024902A1 (en) 1994-03-16 1995-03-16 Ocular tension depressant

Publications (2)

Publication Number Publication Date
DE69522955D1 DE69522955D1 (de) 2001-10-31
DE69522955T2 true DE69522955T2 (de) 2002-05-29

Family

ID=12718322

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533045T Expired - Fee Related DE69533045T2 (de) 1994-03-16 1995-03-16 Okulares Hypotonikum
DE69522955T Expired - Fee Related DE69522955T2 (de) 1994-03-16 1995-03-16 Okulares hypotensium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69533045T Expired - Fee Related DE69533045T2 (de) 1994-03-16 1995-03-16 Okulares Hypotonikum

Country Status (20)

Country Link
US (1) US5925664A (enExample)
EP (2) EP0795326B1 (enExample)
KR (1) KR100211446B1 (enExample)
CN (2) CN1104898C (enExample)
AT (2) ATE266402T1 (enExample)
AU (1) AU684916B2 (enExample)
CZ (1) CZ284395B6 (enExample)
DE (2) DE69533045T2 (enExample)
DK (2) DK0795326T3 (enExample)
ES (2) ES2221872T3 (enExample)
FI (2) FI114897B (enExample)
GR (1) GR3036989T3 (enExample)
HK (1) HK1000551A1 (enExample)
HU (1) HUT74734A (enExample)
MX (1) MX9604109A (enExample)
NO (1) NO311068B1 (enExample)
NZ (1) NZ282485A (enExample)
PT (2) PT1110551E (enExample)
RU (1) RU2123847C1 (enExample)
WO (1) WO1995024902A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201466A3 (en) * 1999-06-11 2003-04-28 Sankyo Co Ocular tension lowering composition for topical administration
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GR20000100281A (el) * 2000-08-17 2002-05-24 Ιωαννης Ματσουκας Ανταγωνιστες του υποδοχεα της αγγεοτενσινης ιι και συνθετικες μεθοδοι για την θεραπεια της υπερτασης και καρδιοαγγειακων ασθενειων
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
ES2535291T3 (es) * 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549049B1 (fr) * 1983-07-13 1986-06-20 Chauvin Blache Lab Nouvelles amidines, leur procede de preparation et leur application therapeutique
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
ZA875052B (en) * 1986-07-11 1989-03-29 Du Pont Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
AU644802B2 (en) * 1989-06-30 1993-12-23 E.I. Du Pont De Nemours And Company Substituted imidazoles
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2229000C (en) * 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
DE4132631A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Imidazolyl-propensaeurederivate
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
ATE199548T1 (de) * 1992-06-02 2001-03-15 Sankyo Co 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
HU219598B (hu) * 1992-12-17 2001-05-28 Sankyo Co. Ltd. Bifenilvegyületek imidazol- és piridinszármazékai, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
WO1995021609A1 (en) * 1994-02-08 1995-08-17 Ciba-Geigy Ag Treatment of normotensive glaucoma with angiotensin ii antagonists

Also Published As

Publication number Publication date
CZ269496A3 (en) 1996-12-11
GR3036989T3 (en) 2002-01-31
HU9602534D0 (en) 1996-11-28
RU2123847C1 (ru) 1998-12-27
AU684916B2 (en) 1998-01-08
KR100211446B1 (ko) 1999-08-02
DK0795326T3 (da) 2001-11-26
NO963854D0 (no) 1996-09-13
NZ282485A (en) 1997-06-24
ES2163501T3 (es) 2002-02-01
FI20041236L (fi) 2004-09-24
EP1110551B1 (en) 2004-05-12
ATE266402T1 (de) 2004-05-15
DE69533045D1 (de) 2004-06-17
HUT74734A (en) 1997-02-28
NO311068B1 (no) 2001-10-08
KR970701542A (ko) 1997-04-12
DK1110551T3 (da) 2004-06-07
FI114897B (fi) 2005-01-31
FI963645A7 (fi) 1996-11-14
PT795326E (pt) 2002-01-30
DE69533045T2 (de) 2005-01-27
CN1104898C (zh) 2003-04-09
EP1110551A3 (en) 2001-08-16
AU1960295A (en) 1995-10-03
FI963645A0 (fi) 1996-09-16
US5925664A (en) 1999-07-20
EP1110551A2 (en) 2001-06-27
MX9604109A (es) 1997-09-30
HK1000551A1 (en) 2002-04-12
EP0795326A1 (en) 1997-09-17
CZ284395B6 (cs) 1998-11-11
CN1148809A (zh) 1997-04-30
WO1995024902A1 (en) 1995-09-21
ATE206050T1 (de) 2001-10-15
EP0795326B1 (en) 2001-09-26
EP0795326A4 (enExample) 1997-09-17
CN1202819C (zh) 2005-05-25
ES2221872T3 (es) 2005-01-16
FI115197B (fi) 2005-03-31
DE69522955D1 (de) 2001-10-31
PT1110551E (pt) 2004-07-30
CN1387846A (zh) 2003-01-01
NO963854L (no) 1996-11-14

Similar Documents

Publication Publication Date Title
DE60029242T2 (de) Arzneien zur begleitenden behandlung von glaukomen
DE69329982T2 (de) 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung
DE69522955T2 (de) Okulares hypotensium
HK1000551B (en) Ocular tension depressant
DE69830615T2 (de) Alicyclische acylierte heterocyclenderivate
DE60020230T2 (de) Den augendruck senkende zusammensetzung zur topischen anwendung
CA2185524C (en) Ocular tension depressant
JP4132798B2 (ja) 局所投与のための眼圧低下組成物
JP2826077B2 (ja) 眼圧低下剤
HK1035485A1 (en) Ocular tension lowering agent
HK1035485B (en) Ocular tension lowering agent
JP3790093B2 (ja) 局所投与用眼圧低下組成物
HK1042050B (en) Ocular tension lowering composition for topical adminstration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee